A5002260379- Research on Leishmaniasis Studies
- Trypanosoma species research and implications
- Toxin Mechanisms and Immunotoxins
- Parasites and Host Interactions
- Plant Pathogens and Fungal Diseases
- Synthesis and Biological Evaluation
- Fungal Infections and Studies
- Mycobacterium research and diagnosis
- Infectious Diseases and Tuberculosis
- Mycorrhizal Fungi and Plant Interactions
- Bioactive Compounds and Antitumor Agents
- vaccines and immunoinformatics approaches
- Reproductive System and Pregnancy
- Antifungal resistance and susceptibility
- Transgenic Plants and Applications
- Leptospirosis research and findings
- Fungal Biology and Applications
- Leprosy Research and Treatment
- Insect and Pesticide Research
- Hepatitis Viruses Studies and Epidemiology
- Yeasts and Rust Fungi Studies
- Monoclonal and Polyclonal Antibodies Research
- Mosquito-borne diseases and control
- Viral Infectious Diseases and Gene Expression in Insects
- Plant-Microbe Interactions and Immunity
Universidade Federal de Minas Gerais
2019-2023
Instituto de Ensino e Pesquisa Santa Casa
2017-2021
Grupo Santa Casa de Belo Horizonte
2017-2018
Abstract Leishmaniases are neglected diseases caused by infection with Leishmania parasites and there currently no prophylactic vaccines. In this study, we designed in silico a synthetic recombinant vaccine against visceral leishmaniasis (VL) called ChimeraT, which contains specific T-cell epitopes from Prohibitin, Eukaryotic Initiation Factor 5a the hypothetical LiHyp1 LiHyp2 proteins. Subcutaneous delivery of ChimeraT plus saponin stimulated Th1 cell-mediated immune response protected mice...
Currently, there is no licensed vaccine to protect against human visceral leishmaniasis (VL), a potentially fatal disease caused by infection with Leishmania parasites. In the current study, recombinant chimeric protein ChimT was developed based on T-cell epitopes identified from immunogenic amastigote proteins LiHyp1, LiHyV, LiHyC and LiHyG. associated adjuvants saponin (Sap) or monophosphoryl lipid A (MPLA) used immunize mice, their immunogenicity protective efficacy were evaluated. Both...
A clioquinol (ICHQ)-containing Pluronic® F127 polymeric micelle system (ICHQ/Mic) was recently shown to be effective against Leishmania amazonensis infection in a murine model. In the present study, ICHQ/Mic tested L. infantum infection. BALB/c mice (n = 12 per group) were infected with stationary promastigotes through subcutaneous injection and, 45 days after challenge, received saline or treated via route empty micelles, ICHQ ICHQ/Mic. addition, animals miltefosine by oral route, as drug...
Background: Leishmaniases are neglected diseases caused by infection with Leishmania parasites and there no human vaccines in use routinely. The purpose of this study was to examine the immunogenicity ChimeraT, a novel synthetic recombinant vaccine against visceral leishmaniasis (VL), incorporated into human-compatible liposome formulation. Methods: BALB/c mice were immunized subcutaneously ChimeraT/liposome vaccine, ChimeraT/saponin adjuvant, or ChimeraT/saline immune responses examined...
There is no suitable vaccine against human visceral leishmaniasis (VL) and available drugs are toxic and/or present high cost. In this context, diagnostic tools should be improved for clinical management epidemiological evaluation of disease. However, the variable sensitivity specificity used antigens limitations, showing necessity to identify new molecules tested in a more sensitive specific serology. study, an immunoproteomics approach was performed Leishmania infantum promastigotes...
visceral leishmaniasis (VL) is a critical public health problem in over ninety countries. The control measures adopted Brazil have been insufficient when it comes to preventing the spread of this overlooked disease. In context, precise diagnosis VL dogs and humans could help reduce number cases Distinct studies for used single recombinant proteins serological assays; however, results variable, mainly relation sensitivity antigens. development multiepitope-based be relevant solving such...
Visceral Leishmaniasis (VL) causes high morbidity and mortality in low-to-middle-income countries worldwide. In this study, we used Laser Direct-Write (LDW) technology to develop a new Lateral Flow Device (LFD) with double-channel geometry on low-cost paper platform as rapid accurate serodiagnostic assay for human VL. This Duplex VL-LFD was based laser-patterned microfluidic device using two recombinant Leishmania proteins, β-tubulin LiHyp1, novel diagnostic antigens. The tested blood/serum...
This paper presents a case of disseminated sporotrichosis in 13-year-old female, originating from rural area Minas Gerais state, Brazil. The patient was hospitalized Santa Casa hospital Belo Horizonte, with hyporexia, prostration, fever and ulcerative lesions, besides anemia, leucopenia sepsis probable cutaneous focus. admitted without proven immunosuppression. She diagnosed cutaneous-disseminated sporotrichosis. drug therapy chosen itraconazole during 12 months, leading to important...
Leishmaniasis is a group of infectious diseases caused by protozoan parasites that belong to the genus Leishmania. Currently, there no human vaccine, and available treatments are associated with toxicity, high cost, emergence resistant strains. These factors highlight need identify new antileishmanial candidates. In this study, we synthesized twenty-four methoxylated cinnamides containing 1,2,3-triazole fragments evaluated their activity against Leishmania braziliensis species, which main...
The co-infection between visceral leishmaniasis (VL) and human immunodeficiency virus (HIV) has increased in several countries the world. current serological tests are not suitable since they present low sensitivity to detect most of VL/HIV cases, a more precise diagnosis should be performed. In this context, study, an immunoproteomics approach was performed using Leishmania infantum antigenic extracts VL, HIV patients sera, besides healthy subjects samples; aiming identify markers for these...